Abstract
Cyclometallated µ-halogeno dimers derived from nitrogen donor ligands (1-phenylpyrazoles, 2-phenylpyridine, and 1-(2′-pyridyl)indole) were treated with unidentate nitrogen and phosphorus donor ligands to give a series of neutral monomeric palladium(II) and platinum(II) complexes. An initial prescreen of the complexes against the mouse lymphoid leukæmia cell line L1210 indicated that the complexes exhibited growth inhibitory activity over a relatively wide concentration range. Two factors that gave rise to increased activity were steric hindrance about the metal centre resulting from hindered ligands such as 2,6-dimethylpyridine, or the presence of a phosphorus donor ligand. Little correlation between palladium and platinum complexes was noted. Four complexes were selected for further in vivo study and, while none of the palladium complexes showed more than marginal activity against P388 leukæmia at doses below toxic levels, one platinum complex with a hindered metal centre did display significant antitumour activity against this model.Key words: cyclometallation, palladium, platinum, cytotoxicity, anticancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
